Clinical Trial Update: Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial exploring SPD422 for reducing platelets in Japanese adults at risk of essential thrombocythemia; study completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• SPD422

Snippet

Sponsor: Shire | Conditions: Essential Thrombocythemia (ET) | Phase 3 | Status: COMPLETED | Results posted: 2013-09-25